Moreover, a radioimmunoconjugate Iodine[131I]-metuximab targeting the CD147 has been developed by our team for the effective treatment of HCC; it also exhibited a significantly prolonged median time to tumor recurrence (Bian et al., 2014). This evidence concerns the gene BSG and neoplasm.